Akebia Therapeutics (AKBA) Earnings Date & Reports

Key Takeaways

• Total revenue declined to $36.9 million in the third quarter of 2026, down from $58.8 million a year earlier and below the roughly $46.9 million consensus estimate.
• Vafseo net product revenue rose 3% year over year to $14.8 million, while Auryxia revenue fell to $20.0 million under pressure from generic competition.
• The company reported a GAAP net loss of $14.4 million, or $0.05 per share, compared with net income of $0.5 million in the prior-year quarter.
• Akebia ended the quarter with $159.3 million in cash and cash equivalents, supported in part by at-the-market (ATM) equity proceeds.
• Management outlined post-TDAPA pricing of roughly $1,000 to $1,500 per patient annually as Vafseo transitions to bundled reimbursement on January 1, 2027.
• For more on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast.
• Discover new market opportunities with Trending AI Robots.

Earnings Context and Why It Matters

Akebia Therapeutics is navigating a pivotal transition for its lead commercial product, Vafseo (vadadustat), a treatment for anemia associated with chronic kidney disease in adults on dialysis. The third quarter of 2026 marks one of the final reporting periods before Vafseo's TDAPA (Transitional Drug Add-on Payment Adjustment) window expires at the start of 2027, shifting the drug from separate add-on reimbursement into the standard dialysis bundle. This report matters because it reveals whether Vafseo's patient momentum can offset a steep decline in legacy Auryxia revenue and how sharply management expects pricing to reset. Investors are also weighing promising clinical data from the VOICE and VOCAL studies against a softer near-term revenue trajectory.

Reported Results

For the third quarter ended September 30, 2026, Akebia reported total revenue of $36.9 million, a 37% decline from $58.8 million in the same period last year and below the consensus of approximately $46.9 million. Product revenue was led by Vafseo at $14.8 million, up only 3% year over year despite roughly 140% growth in patients on therapy, largely reflecting an inventory drawdown tied to lower-than-expected dosing and dialysis compliance. Auryxia revenue dropped to $20.0 million from $42.5 million a year earlier amid generic competition and pricing pressure.

The company posted a GAAP net loss of $14.4 million, or $0.05 per share, swinging from net income of $0.5 million in the prior-year quarter. This missed the consensus loss estimate of about $0.03 per share. Cost of goods sold declined to $6.4 million, while research and development expenses rose to $16.2 million and selling, general, and administrative expenses fell to $23.5 million. The quarter included a $1.3 million restructuring charge.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are monitoring a single ticker like AKBA or scanning entire sectors, the AI Screener offers a structured way to identify signals worth investigating further.

Market Reaction and Investor Sentiment

Akebia's shares faced notable pressure following the report, as the revenue miss and the newly quantified post-TDAPA pricing reset overshadowed a strengthened clinical narrative. Investors have long viewed Vafseo's expansion as the core growth engine, and the disclosure of a $1,000 to $1,500 annual per-patient cost of therapy represents a meaningful step down from earlier market assumptions. The company's strongest clinical evidence to date, including VOICE data showing a roughly 10% reduction in hospitalizations versus an ESA (erythropoiesis-stimulating agent), was delivered alongside a reset of forward economics, creating a clear tension in sentiment. Auryxia's accelerating decline added to the cautious tone.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important date on Akebia's calendar is January 1, 2027, when Vafseo's TDAPA period ends and reimbursement shifts into the dialysis bundle. Management expects continued patient growth in the fourth quarter, driven primarily by mid-sized dialysis organizations, while also anticipating further inventory drawdowns ahead of the transition.

Investors should monitor several factors. First, the pace of adoption at large dialysis providers such as DaVita and Fresenius will be critical, as management described DaVita's planned rollout as slow but deliberate, with a more significant push expected in early 2027. Second, the trajectory of Auryxia revenue remains a headwind as generics continue to erode the legacy franchise.

Finally, the company's rare kidney disease pipeline, including Phase 2 programs for FSGS (focal segmental glomerulosclerosis) and a basket trial in C3G, IgAN (immunoglobulin A nephropathy), and lupus nephritis, offers longer-term catalysts. With $159.3 million in cash and plans to refinance its senior secured term loan, Akebia expects its resources to fund operations for at least the next two years, though execution on Vafseo's post-TDAPA launch will remain the central driver of the investment thesis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations